Por Renan Filho · 2026-10-19**Lead**
A fresh wave of attention has surrounded the documentary “You Can See Everything,” which chronicles the rise and fall of Elizabeth Holmes and her blood-testing startup Theranos. In a widely circulated opinion piece, the film is hailed as a must-watch, with the reviewer asserting that the documentary not only meets but exceeds the considerable hype generated by its release. The review, published this week, has sparked renewed discussion about the enduring fascination with Holmes and the lessons still being drawn from the Theranos scandal.
**Context**
Elizabeth Holmes was once celebrated as a visionary entrepreneur, founding Theranos in 2003 with the promise of revolutionizing blood testing using a few drops of blood from a finger prick. At its peak, the company was valued at $9 billion, and Holmes graced magazine covers as the world’s youngest self-made female billionaire. However, investigative reporting by The Wall Street Journal in 2015 revealed that the company’s technology was largely fraudulent, leading to a cascade of legal battles. Holmes was convicted in 2022 on multiple counts of fraud and sentenced to over 11 years in prison, a sentence she is currently serving.
The Theranos saga has already been the subject of several documentaries, including HBO’s “The Inventor: Out for Blood in Silicon Valley” and a Hulu miniseries starring Amanda Seyfried. “You Can See Everything” distinguishes itself by claiming access to never-before-seen footage and interviews with former employees and associates who have not spoken publicly before. The documentary’s release on a major streaming platform has generated significant buzz, with early viewers praising its intimate portrayal of Holmes’s psychology and the corporate culture inside Theranos.
The opinion piece in question argues that despite the saturation of Theranos content, “You Can See Everything” manages to offer a fresh perspective. The reviewer notes that the documentary avoids the trap of simply rehashing known facts, instead delving into the emotional and ethical dimensions of the story. It highlights how the filmmakers juxtapose Holmes’s charismatic public persona with the devastating consequences for patients and investors. The review also commends the documentary for its balanced approach, giving voice to both Holmes’s defenders and her victims.
**Analysis**
The timing of this review is significant. Public interest in Elizabeth Holmes remains high, fueled by ongoing appeals and the broader cultural conversation about accountability in Silicon Valley. The documentary arrives at a moment when the tech industry is grappling with questions of ethics, regulation, and the cult of personality around founders. The opinion piece underscores that “You Can See Everything” is not merely a true-crime story but a cautionary tale about ambition, deception, and the failure of oversight.
Moreover, the review’s enthusiastic reception suggests that audiences are still hungry for nuanced examinations of the Theranos case. While some critics have questioned whether another documentary is necessary, the opinion piece argues that this film fills a gap by focusing on the human cost of the fraud. It points to interviews with patients who received inaccurate test results, as well as former employees who describe a toxic work environment driven by Holmes’s relentless pursuit of success. The reviewer contends that these elements make the documentary emotionally resonant and intellectually satisfying.
The impact of such a positive review cannot be underestimated. In an era of fragmented media, a strong endorsement can drive viewership and shape public discourse. The opinion piece has already been shared widely on social media, with many users echoing its praise. Some commentators have noted that the documentary could influence how future fraud cases are covered, especially in the tech sector. The review also raises questions about the ethics of documentary filmmaking itself, particularly when the subject is a convicted felon who continues to maintain her innocence.
**Sources**
The information in this article is based on the published opinion piece reviewing “You Can See Everything,” as well as publicly available background on the Theranos case, including court records and previous media reports from outlets such as The Wall Street Journal, The New York Times, and Reuters. No direct quotes or specific data from the review have been reproduced, and all descriptions of the documentary’s content are drawn from the reviewer’s stated observations.